M&A Deal Summary |
|
---|---|
Date | 2014-12-16 |
Target | Allylix |
Sector | Chemicals |
Buyer(s) | Evolva Holding |
Deal Type | Add-on Acquisition |
Deal Value | 46M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2004 |
Sector | Life Science |
Employees | 65 |
Revenue | 8M CHF (2020) |
Evolva Holding SA is a provider of biosynthetic and evolutionary technologies to create and optimise small molecule compounds and their production routes. Evolva Holding was incorporated in 2004 and is based in Reinach, Switzerland.
DEAL STATS | # |
---|---|
Overall | 2 of 2 |
Sector (Chemicals) | 1 of 1 |
Type (Add-on Acquisition) | 2 of 2 |
State (California) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2014) | 2 of 2 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-07-31 |
Prosarix
Cambridge, United Kingdom Prosarix Ltd. is a biotechnology company. Prosarix develops computational products for the biotech and pharmaceutical sectors. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-12-17 |
Evolva Holding - EV-035
Switzerland EV-035 is a series of novel small molecule broad spectrum antibiotics of the 4-oxoquinolizine class and targets bacterial type IIa topoisomerase. |
Sell | - |